270 related articles for article (PubMed ID: 19433856)
21. The antileukemia roles of PP242 alone or in combination with daunorubicin in acute leukemia.
Shi F; Yang X; Gong Y; Shi R; Yang X; Naren D; Wu J
Anticancer Drugs; 2015 Apr; 26(4):410-21. PubMed ID: 25535978
[TBL] [Abstract][Full Text] [Related]
22. Design of nucleotide-mimetic and non-nucleotide inhibitors of the translation initiation factor eIF4E: Synthesis, structural and functional characterisation.
Soukarieh F; Nowicki MW; Bastide A; Pöyry T; Jones C; Dudek K; Patwardhan G; Meullenet F; Oldham NJ; Walkinshaw MD; Willis AE; Fischer PM
Eur J Med Chem; 2016 Nov; 124():200-217. PubMed ID: 27592390
[TBL] [Abstract][Full Text] [Related]
23. Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation.
Tan J; Ye J; Song M; Zhou M; Hu Y
J Biochem Mol Toxicol; 2018 Jan; 32(1):. PubMed ID: 29112301
[TBL] [Abstract][Full Text] [Related]
24. Targeting of phospho-eIF4E by homoharringtonine eradicates a distinct subset of human acute myeloid leukemia.
Zhou H; Xu RZ; Gu Y; Shi PF; Qian S
Leuk Lymphoma; 2020 May; 61(5):1084-1096. PubMed ID: 29334312
[TBL] [Abstract][Full Text] [Related]
25. The eukaryotic translation initiation factor eIF4E reprograms alternative splicing.
Ghram M; Morris G; Culjkovic-Kraljacic B; Mars JC; Gendron P; Skrabanek L; Revuelta MV; Cerchietti L; Guzman ML; Borden KLB
EMBO J; 2023 Apr; 42(7):e110496. PubMed ID: 36843541
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of eIF4E cooperates with chemotherapy and immunotherapy in renal cell carcinoma.
Cao J; Sun X; Zhang X; Chen D
Clin Transl Oncol; 2018 Jun; 20(6):761-767. PubMed ID: 29086249
[TBL] [Abstract][Full Text] [Related]
27. Ribavirin is not a functional mimic of the 7-methyl guanosine mRNA cap.
Yan Y; Svitkin Y; Lee JM; Bisaillon M; Pelletier J
RNA; 2005 Aug; 11(8):1238-44. PubMed ID: 16043507
[TBL] [Abstract][Full Text] [Related]
28. Targeting eIF4E signaling with ribavirin as a sensitizing strategy for ovarian cancer.
Jin J; Xiang W; Wu S; Wang M; Xiao M; Deng A
Biochem Biophys Res Commun; 2019 Mar; 510(4):580-586. PubMed ID: 30739792
[TBL] [Abstract][Full Text] [Related]
29. Azacitidine Is Synergistically Lethal with XPO1 Inhibitor Selinexor in Acute Myeloid Leukemia by Targeting XPO1/eIF4E/c-MYC Signaling.
Long H; Hou Y; Li J; Song C; Ge Z
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047788
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of eukaryotic translation initiation factor 4E is effective against chemo-resistance in colon and cervical cancer.
Xi C; Wang L; Yu J; Ye H; Cao L; Gong Z
Biochem Biophys Res Commun; 2018 Sep; 503(4):2286-2292. PubMed ID: 29959920
[TBL] [Abstract][Full Text] [Related]
31. Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities.
Topisirovic I; Ruiz-Gutierrez M; Borden KL
Cancer Res; 2004 Dec; 64(23):8639-42. PubMed ID: 15574771
[TBL] [Abstract][Full Text] [Related]
32. Targeting translation: eIF4E as an emerging anticancer drug target.
Lu C; Makala L; Wu D; Cai Y
Expert Rev Mol Med; 2016 Jan; 18():e2. PubMed ID: 26775675
[TBL] [Abstract][Full Text] [Related]
33. Pharmacodynamic and therapeutic pilot studies of single-agent ribavirin in patients with human papillomavirus-related malignancies.
Burman B; Drutman SB; Fury MG; Wong RJ; Katabi N; Ho AL; Pfister DG
Oral Oncol; 2022 May; 128():105806. PubMed ID: 35339025
[TBL] [Abstract][Full Text] [Related]
34. Understanding and Targeting the Eukaryotic Translation Initiation Factor eIF4E in Head and Neck Cancer.
Culjkovic B; Borden KL
J Oncol; 2009; 2009():981679. PubMed ID: 20049173
[TBL] [Abstract][Full Text] [Related]
35. A blood pact: the significance and implications of eIF4E on lymphocytic leukemia.
Venturi V; Masek T; Pospisek M
Physiol Res; 2018 Jul; 67(3):363-382. PubMed ID: 29527921
[TBL] [Abstract][Full Text] [Related]
36. The antiviral drug ribavirin does not mimic the 7-methylguanosine moiety of the mRNA cap structure in vitro.
Westman B; Beeren L; Grudzien E; Stepinski J; Worch R; Zuberek J; Jemielity J; Stolarski R; Darzynkiewicz E; Rhoads RE; Preiss T
RNA; 2005 Oct; 11(10):1505-13. PubMed ID: 16131589
[TBL] [Abstract][Full Text] [Related]
37. The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data.
Rutherford SC; Stewart EN; Chen Z; Chadburn A; Wehrli NE; van Besien K; Martin P; Furman RR; Leonard JP; Cerchietti L
Leuk Lymphoma; 2018 Jan; 59(1):256-258. PubMed ID: 28573908
[No Abstract] [Full Text] [Related]
38. Eukaryotic translation initiation factor 4E activity is modulated by HOXA9 at multiple levels.
Topisirovic I; Kentsis A; Perez JM; Guzman ML; Jordan CT; Borden KL
Mol Cell Biol; 2005 Feb; 25(3):1100-12. PubMed ID: 15657436
[TBL] [Abstract][Full Text] [Related]
39. mRNA export and cancer.
Siddiqui N; Borden KL
Wiley Interdiscip Rev RNA; 2012; 3(1):13-25. PubMed ID: 21796793
[TBL] [Abstract][Full Text] [Related]
40. Elevated Translation Initiation Factor eIF4E Is an Attractive Therapeutic Target in Multiple Myeloma.
Li S; Fu J; Lu C; Mapara MY; Raza S; Hengst U; Lentzsch S
Mol Cancer Ther; 2016 Apr; 15(4):711-9. PubMed ID: 26939700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
